Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Curran

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Frontiers in Oncology|October 7, 2015
Editorial: Advances in Combination Tumor ImmunotherapyMichael A Curran, Bernard A Fox, William L Redmond
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2010
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsMichael A Curran, Welby Montalvo, Hideo Yagita, et al.
Immunobiology|March 31, 2012
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe"Michael A Curran, Margaret K Callahan, Sumit K Subudhi, et al.
The Journal of Clinical Investigation|June 17, 2006
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsSergio A Quezada, Karl S Peggs, Michael A Curran, et al.
Cell Reports. Medicine|November 19, 2025
Voices: Future directions in targeting the tumor microenvironmentTanja de Gruijl, Catherine Sautès-Fridman, Daniela S Thommen, et al.
Annual Review of Medicine|October 26, 2021
Hypoxia Reduction Sensitizes Refractory Cancers to ImmunotherapyPriyamvada Jayaprakash, Paolo Dario Angelo Vignali, Greg M Delgoffe, et al.
Journal for Immunotherapy of Cancer|January 10, 2019
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapyKerstin Kapp, Barbara Volz, Michael A Curran, et al.
Plos One|May 12, 2011
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionMichael A Curran, Myoungjoo Kim, Welby Montalvo, et al.
Cell Transplantation|November 30, 2004
Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantationElizabeth S Fenjves, M Sofia Ochoa, Carlota Gay-Rabinstein, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2019
Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacyCasey R Ager, Huaping Zhang, Zhanlei Wei, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|October 7, 2015
Editorial: Advances in Combination Tumor ImmunotherapyMichael A Curran, Bernard A Fox, William L Redmond
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2010
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsMichael A Curran, Welby Montalvo, Hideo Yagita, et al.
Immunobiology|March 31, 2012
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe"Michael A Curran, Margaret K Callahan, Sumit K Subudhi, et al.
The Journal of Clinical Investigation|June 17, 2006
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsSergio A Quezada, Karl S Peggs, Michael A Curran, et al.
Cell Reports. Medicine|November 19, 2025
Voices: Future directions in targeting the tumor microenvironmentTanja de Gruijl, Catherine Sautès-Fridman, Daniela S Thommen, et al.
Annual Review of Medicine|October 26, 2021
Hypoxia Reduction Sensitizes Refractory Cancers to ImmunotherapyPriyamvada Jayaprakash, Paolo Dario Angelo Vignali, Greg M Delgoffe, et al.
Journal for Immunotherapy of Cancer|January 10, 2019
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapyKerstin Kapp, Barbara Volz, Michael A Curran, et al.
Plos One|May 12, 2011
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionMichael A Curran, Myoungjoo Kim, Welby Montalvo, et al.
Cell Transplantation|November 30, 2004
Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantationElizabeth S Fenjves, M Sofia Ochoa, Carlota Gay-Rabinstein, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2019
Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacyCasey R Ager, Huaping Zhang, Zhanlei Wei, et al.
Pageof 9